Akebia Says Three-Times-Weekly Vadadustat Met Primary Endpoint Of Non-Inferiority To Mircera In Hemoglobin Control In Dialysis Patients
Share
Why It Matters
Akebia's new medicine worked about as well as an older one. This is good news for the company and shows the drug is safe to use.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.